Effect of radiotherapy on survival in advanced hepatocellular carcinoma patients treated with sorafenib: a nationwide cancer-registry-based study

doi:10.1038/s41598-021-81176-w

CNU IR > Pharmacy and Science > Dept. of Cosmetic Science and institute of cosmetic science > Periodical Articles > Item 310902800/34496

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34496

Title:	Effect of radiotherapy on survival in advanced hepatocellular carcinoma patients treated with sorafenib: a nationwide cancer-registry-based study
Authors:	Chu, Shou-Sheng Kuo, Yu-Hsuan Liu, Wen-Shan Wang, Shih-Chang Ho, Chung-Han Chen, Yi-Chen Yang, Ching-Chieh Wu, Hung-Chang
Contributors:	Chi Mei Med Ctr, Dept Radiat Oncol Chi Mei Med Ctr, Dept Hematol & Oncol Chia Nan Univ Pharm & Sci, Dept Cosmet Sci Kaohsiung Vet Gen Hosp, Dept Radiat Oncol Meiho Univ, Dept Nursing Natl Def Med Ctr, Sch Med Antai Med Care Corp Antai Tian Sheng Mem Hosp, Dept Radiat Oncol Chi Mei Med Ctr, Dept Med Res Chia Nan Univ Pharm & Sci, Dept Hosp & Hlth Care Adm Chia Nan Univ Pharm & Sci, Dept Pharm
Keywords:	RADIATION-THERAPY OUTCOMES CIRRHOSIS PATTERNS PHASE-2
Date:	2021
Issue Date:	2023-11-11 11:58:33 (UTC+8)
Publisher:	NATURE PORTFOLIO
Abstract:	Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC) patients. This study aims to determine whether combining radiotherapy with sorafenib administration increases its efficacy. The study cohort included 4763 patients with diagnosed advanced HCC who received sorafenib between January 2012 and December 2015, as reported in medical records in the Taiwan Cancer Registry database. The effect of sorafenib with or without radiotherapy on survival was calculated using the Kaplan-Meier method and compared using the log-rank test. A Cox proportional hazards model was used for multivariate analysis. Patients receiving sorafenib plus radiotherapy had greater 1-year survival than did those receiving sorafenib alone (P<0.001). Uni- and multivariate analyses also showed that radiotherapy increased survival after adjusting for confounders (adjusted HR 0.57; 95% CI 0.51-0.63). Further stratified analysis according to the timing of radiotherapy relative to sorafenib treatment revealed that patients who underwent radiotherapy after sorafenib had greater 1-year survival than did those undergoing radiotherapy within sorafenib use or sorafenib alone (adjusted HR 0.39; 95% CI 0.27-0.54). Combined treatment with sorafenib and radiotherapy results in greater HCC patient survival and should be considered an option for treating this challenging disease.
Relation:	SCI REP-UK, v.11, n.1, pp.1614
Appears in Collections:	[Dept. of Cosmetic Science and institute of cosmetic science] Periodical Articles

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	159	View/Open
s41598-021-81176-w.pdf		1135Kb	Adobe PDF	77	View/Open

Loading...